This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Treatment of Campylobacter jejuni

Authoring team

Antibiotic therapy is recommended mainly for the dysenteric Campylobacter gastroenteritis and most efficacious when started within 3 days after onset of the disease. They are not recommended in uncomplicated cases. (1)

Macrolides (e.g., azithromycin, erythromycin) are generally the treatment of choice in both children and adults (2):

  • azithromycin is often the preferred macrolide due to the convenience of single dosing
  • erythromycin is used less commonly, but is the recommended drug in pregnancy (3)

In children, seek expert advice. Alternative agents are ciprofloxacin or vancomycin (4)

Check the summary of product characteristics of drugs mentioned before prescribing.

References:

  1. Centers for Disease Control and Prevention. CDC Yellow Book 2024: traveler's health. Section 5: travel-associated infections & diseases​ - campylobacteriosis. May 2023 [internet publication].
  2. Riddle MS, DuPont HL, Connor BA. ACG clinical guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. Am J Gastroenterol. 2016 May;111(5):602-22.
  3. World Gastroenterology Organisation (WGO). WGO practice guideline: acute diarrhea. 2012 [internet publication].
  4. Bruzzese E, Giannattasio A, Guarino A. Antibiotic treatment of acute gastroenteritis in children. F1000Research. 2018;7:193.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.